# Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

> **NCT00772889** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 971 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza vaccine GSK2186877A
- **BIOLOGICAL:** GSK Biologicals' Fluarix™

## Key facts

- **NCT ID:** NCT00772889
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-09
- **Primary completion:** 2009-12-15
- **Final completion:** 2009-12-15
- **Target enrollment:** 971 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00772889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00772889, "Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00772889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*